Ketamine for Treatment-Resistant Depression
Mustansiriya Medical Journal July 1, 2021 Peer reviewed DOI: 10.4103/mj.mj_15_21
Summary
Major depressive disorder (MDD) affects about 350 million people globally, leading to significant disability. Antidepressants help relieve symptoms in around 50% of cases, but this rate drops for those with treatment-resistant depression (TRD). Ketamine is an older anesthetic showing promise as a fast-acting antidepressant for TRD patients, addressing important clinical considerations like administration route and dosing. Additionally, ketamine may also be beneficial for post-traumatic stress disorder and acute suicidal ideation.
Study at a glance
| Population | individuals with major depressive disorder and treatment-resistant depression |
|---|---|
| Key finding | Ketamine shows promise as a fast-acting antidepressant in treatment-resistant depression patients. |
Abstract
Major depressive disorder (MDD) is of influence on about 350 million individuals worldwide, which is causing disability consecution and damaging consequences to the affected community and individuals. Treatments as antidepressant are affecting the system of monoamine where symptoms of depressive were relived in about 50% of cases. Such ratio turns into obviously low in depressed persons who failed already to cure following 2 or additional antidepressant drugs at sufficient duration and doses regarding it a treatment-resistant depression (TRD). There is an obvious requisite for quick action and influenced treatments. Ketamine (KMN) is considered an anesthetic old drug that has a promising quick action as an antidepressant in TRD patients with MDD, concentrating on clinical issues, i.e. administration route, dose, and action duration. Other indication proposes that KMN might be influenced in stress disorder as posttraumatic and ideation as acute suicidal.